The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia
Sponsor: Milestone Pharmaceuticals Inc.
Listed as NCT05763953, this PHASE2 trial focuses on Paroxysmal Supraventricular Tachycardia and remains actively recruiting participants. Sponsored by Milestone Pharmaceuticals Inc., it has been updated 6 times since 2023, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Apr 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Milestone Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .